

**T K Lim**

Department of Medicine, National University of Singapore, Singapore

**B W Lee**

Department of Paediatrics, National University of Singapore, Singapore

Correspondence to: Dr B W Lee, Department of Paediatrics, National University of Singapore, Singapore; paeleebw@nus.edu.sg

doi: 10.1136/thx.2005.050435

The authors thank Intercontinental Medical Statistics (Asia) Pte Ltd for providing data on sales of asthma medications in Singapore.

Competing interests: none declared.

**References**

- 1 **Suissa S, Ernst P.** Inhaled corticosteroids: impact on asthma morbidity and mortality. *J Allergy Clin Immunol* 2001;**107**:937–44.
- 2 **Bjor O, Braback L.** A retrospective population based trend analysis on hospital admissions for lower respiratory illness among Swedish children from 1987 to 2000. *BMC Public Health* 2003;**3**:22.
- 3 **Suissa S, Ernst P, Benayoun S, et al.** Low-dose inhaled corticosteroids and the prevention of death from asthma. *N Engl J Med* 2000;**343**:332–6.
- 4 **Suissa S, Ernst P.** Use of anti-inflammatory therapy and asthma mortality in Japan. *Eur Respir J* 2003;**21**:101–4.
- 5 **Spitzer WO, Suissa S, Ernst P, et al.** The use of beta-agonists and the risk of death and near death from asthma. *N Engl J Med* 1992;**326**:501–6.


**Non-invasive monitoring of CO<sub>2</sub> levels in patients using NIV for AECOPD**

Non-invasive ventilation (NIV) is the treatment of choice for persistent hypercapnic ventilatory failure during acute exacerbations of chronic obstructive pulmonary disease (AECOPD), despite optimal medical treatment.<sup>1,2</sup> Assessment of the partial arterial pressure of carbon dioxide (PaCO<sub>2</sub>) is the “gold standard” for the evaluation of the adequacy of alveolar ventilation in this setting. However, repeated intermittent invasive arterial puncture carries inherent risks, including pain.<sup>3</sup> Transcutaneous measurement of carbon dioxide (TcPCO<sub>2</sub>) theoretically appears more appropriate for monitoring PaCO<sub>2</sub>. This measurement is based on the observation that CO<sub>2</sub> has a high tissue solubility and diffuses through the skin. While available data as to the precision of TcPCO<sub>2</sub> measurements have given conflicting results,<sup>4–6</sup> no study has attempted to assess simultaneous recordings of TcPCO<sub>2</sub> and PaCO<sub>2</sub> in patients requiring NIV for AECOPD.


We prospectively studied the agreement between TcPCO<sub>2</sub> and PaCO<sub>2</sub> measurements in 22 consecutive patients with AECOPD admitted to the respiratory support unit (RSU) from the emergency department with persistent ventilatory failure (PaCO<sub>2</sub> ≥6 kPa) requiring NIV treatment. Paired arterial blood gas samples taken from the radial artery and TcPCO<sub>2</sub> measurements were made on arrival in the RSU and 1 and 4 hours after commencing NIV. Patients were also given bronchodilators by nebuliser, corticosteroids, and antibiotics. Each subject gave their informed consent following a detailed presentation of the study objectives and protocol.

Thirteen women and nine men of mean (SD) age 72 (10) years and mean (SD) body weight 67 (13) kg were enrolled in the study. On arrival at the RSU, mean (SD) systolic blood pressure (BP) was 138 (33) mm Hg and diastolic BP was 70 (14) mm Hg. No patient received vasopressor or inotropic support. Arterial pH on arrival at the RSU was 7.27 (0.06). TcPCO<sub>2</sub> measurements were performed with a capnograph (Tosca Monitor; Linde Medical Sensors, Basel, Switzerland). The monitor measures TcPCO<sub>2</sub> using a Stow-Severinghaus electrode with a single ear sensor which works at 42°C to enhance blood flow in capillaries below the sensor. TcPCO<sub>2</sub> is measured by determining the pH of an electrolyte solution. The change in pH is proportional to the logarithm of the change in TcPCO<sub>2</sub>. Reassembly of the sensor—which constitutes an electrolyte solution, a spacer, and a gas permeable Teflon membrane—has to be done every 14 days. The monitor displays when the sensor needs a new membrane. The system is equipped with an integrated unit for fully automatic calibration before measurements. In vitro response times are typically below 50 seconds.

Agreement between transcutaneous and arterial values for CO<sub>2</sub> was tested over a



**Figure 1** Correlation between TcPCO<sub>2</sub> and PaCO<sub>2</sub> measurements in 22 subjects (A) on arrival in the RSU and (B) 1 hour and (C) 4 hours after commencing non-invasive ventilation for an acute exacerbation of COPD.



**Figure 2** Bias of TcPCO<sub>2</sub> compared with PaCO<sub>2</sub> (d) and SD of bias (s) in 22 subjects (A) on arrival in the RSU and (B) 1 hour and (C) 4 hours after commencing non-invasive ventilation for an acute exacerbation of COPD. Values of (TcPCO<sub>2</sub> – PaCO<sub>2</sub>) are plotted against the mean values of TcPCO<sub>2</sub> and PaCO<sub>2</sub> as described by Bland and Altman.<sup>7</sup>

range of 5–22 kPa and calculated using Pearson’s coefficient of correlation. Both measurements were highly correlated on arrival in the RSU ( $r = 0.99$ ,  $p < 0.0001$ ) and 1 hour ( $r = 0.99$ ,  $p < 0.0001$ ) and 4 hours after commencing NIV ( $r = 0.98$ ,  $p < 0.0001$ ; fig 1). However, in two of our measurements—interestingly, at a lower PaCO<sub>2</sub>—the agreement was less strong. We also calculated the bias and the limits of agreement between the parameters as described by Bland and Altman;<sup>7</sup> 95% of the values were within the limits of agreement on arrival in the RSU and 1 and 4 hours after commencing NIV (fig 2). There were no adverse effects from or patient discomfort with the heating electrode.

These findings suggest that TcPCO<sub>2</sub> measurements are appropriate for clinical application in estimating the ventilatory response to NIV in patients with hypercapnic ventilatory failure due to AECOPD. However, a larger and more detailed study is needed to confirm these preliminary findings. TcPCO<sub>2</sub> measurements allow real time estimation of CO<sub>2</sub> levels over a prolonged period and therefore facilitate proactive rather than reactive ventilator manipulations. Moreover,

TcPco<sub>2</sub> measurements may help in deciding the timing of arterial sampling and may therefore considerably reduce the frequency of painful invasive arterial sampling.

**M Cox, R Kemp, S Anwar, V Aithey, T Aung, E D Moloney**

Department of Respiratory Medicine, Northern General Hospital, Sheffield, UK

Correspondence to: Dr E D Moloney, Chest Clinic, Northern General Hospital, Sheffield S5 7AU, UK; Edward.Moloney@sth.nhs.uk

doi: 10.1136/thx.2005.051664

Competing interests: none declared.

## References

- National Collaborating Centre for Chronic Conditions.** Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. *Thorax* 2004;**59**(Suppl 1):1–232.
- British Thoracic Society Standards of Care Committee.** Non-invasive ventilation in acute respiratory failure. *Thorax* 2002;**57**:192–211.
- Dar K, Williams T, Aitken R, et al.** Arterial versus capillary sampling for analysing blood gas pressures. *BMJ* 1995;**310**:24–5.
- Cuvelier A, Grigoriu B, Molano LC, et al.** Limitations of transcutaneous carbon dioxide measurements for assessing long-term mechanical ventilation. *Chest* 2005;**127**:1744–8.
- Rosner V, Hannhart B, Chabot F, et al.** Validity of transcutaneous oxygen/carbon dioxide pressure measurement in the monitoring of mechanical ventilation in stable chronic respiratory failure. *Eur Respir J* 1999;**13**:1044–7.
- Janssens JP, Howarth-Frey C, Chevrolet JC, et al.** Transcutaneous PCO<sub>2</sub> to monitor noninvasive mechanical ventilation in adults. *Chest* 1998;**113**:768–73.
- Bland M, Altman DG.** Statistical methods for assessing agreement between two methods of clinical measurement. *Lancet* 1986;**1**:307–10.

## Per lesion analysis is misleading

We read with interest the randomised controlled trial by Häußinger and co-workers<sup>1</sup> which compared autofluorescence bronchoscopy (AFB) plus white light bronchoscopy (WLB) with WLB alone for detecting precancerous lesions. The authors stratified their patients into four different risk groups before randomisation. They also excluded from analysis biopsy samples taken from or next to visible tumours. Their major findings suggested that WLB plus AFB was significantly superior to WLB alone for detecting precancerous lesions.

While we appreciate the clinical significance of their major findings, we found the per lesion analysis adopted in the paper misleading for evaluating the sensitivity, specificity, and predictive values of AFB plus WLB. They obtained biopsy tissue from all suspicious areas and at least two areas of non-suspicious appearance in each subject.<sup>1</sup> Thus, each study subject contributed an arbitrary number of biopsy samples which might also be dependent on each other when they were taken from the same subject. Other investigators also adopted a similar approach in a loose manner.<sup>2–4</sup> Apart from causing confusion, a per lesion analysis does not inform clinical decision. It may also partly explain the high variability of sensitivity and specificity in different studies.<sup>1</sup>

Sensitivity, specificity, and predictive values are clinically relevant because they inform us how well a test will perform in certain clinical contexts. The preferred approach for ascertaining these parameters is therefore a per subject analysis in which each subject is labelled as either test positive or test negative and the test status is matched against the representative histological result of the subject's biopsy. Study subjects should also be representative of those encountered in a typical clinical scenario.

To illustrate the potential flaw in a per lesion analysis, let us vary the number of biopsy samples taken arbitrarily from non-suspicious sites in both arms (WLB plus AFB arm versus WLB alone) of the quoted study<sup>1</sup> without changing negative predictive values and the number of biopsy samples from suspicious sites (table 1). When the number of non-suspicious biopsy samples is doubled or tripled, the sensitivity, specificity and prevalence in each arm change accordingly. The sensitivity of WLB plus AFB relative to that of WLB alone also changes from 1.42 (95% CI 0.94 to 2.15) to 1.72 (95% CI 1.04 to 2.83) and 1.94 (95% CI 1.13 to 3.33), respectively. Likewise, the prevalence of pre-invasive lesions detected by WLB plus AFB relative to that detected by WLB alone changes from 1.61 (95% CI 0.93 to 2.79) to 1.37 (95% CI 0.84 to 2.22) and 1.23 (95% CI 0.79 to 1.90), respectively. Thus, a per lesion approach could generate different sets of arbitrary values according to an arbitrary change in the number of biopsy samples taken from non-suspicious areas.

**K-C Chang, C-C Leung, C-M Tam**

TB and Chest Service, Centre for Health Protection, Department of Health, Hong Kong

Correspondence to: Dr K-C Chang, Yaumatei Chest Clinic, Yaumatei Jockey Club Polyclinic, 145 Battery Street, Kowloon, Hong Kong; ymtcc@dh.gov.hk

Dr Häußinger was asked to comment but no reply had been received by the time this issue of *Thorax* went to press.

Funding: none.

Competing interests: none.

## References

- Häußinger K, Becker H, Stanzel F, et al.** Autofluorescence bronchoscopy with white light bronchoscopy compared with white light

bronchoscopy alone for the detection of precancerous lesions: a European randomised controlled multicentre trial. *Thorax* 2005;**60**:496–503.

- Lam S, Kennedy T, Unger M, et al.** Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. *Chest* 1998;**113**:696–702.
- Kurie JM, Lee JS, Morice RC, et al.** Autofluorescence bronchoscopy in the detection of squamous metaplasia and dysplasia in current and former smokers. *J Natl Cancer Inst* 1998;**90**:991–5.
- Moro-Sibilot D, Jeanmart M, Lantuejoul S, et al.** Cigarette smoking, preinvasive bronchial lesions, and autofluorescence bronchoscopy. *Chest* 2002;**122**:1902–8.

## A&E department: a missed opportunity for diagnosis of TB?

The World Health Organization declared tuberculosis (TB) to be a global emergency in 1993. Since then there has been a resurgence of TB in England and Wales, particularly in London.<sup>1,2</sup> Early diagnosis, particularly of infectious cases, is a major factor in the success of control programmes.<sup>3</sup> In the UK, TB continues to disproportionately affect vulnerable groups—including the homeless, illicit drug users, alcoholics, and immigrants recently arrived from high prevalence countries. These groups frequently find it difficult to access appropriate health care and often rely on Accident and Emergency (A&E) departments for health-care provision. We examined how frequently patients with TB attended the local A&E department before their diagnosis and whether their A&E attendances led to a diagnosis of TB being made.

From January 2001 to March 2002 there were 130 notifications of TB at University College London Hospitals. For each patient with TB the A&E department records were examined for the 6 month period before the date of diagnosis. Forty one (31%) of the 130 patients attended the A&E department on 51 occasions during the 6 months prior to diagnosis. Thirty six of the 41 (88%) had no access to a general practitioner; of the remainder, the majority self-referred to A&E. The demographic characteristics of patients attending A&E and the 130 patients were similar. Of A&E attenders, 17 were black African, 13 were Asian, and 11 were white. Eighteen had underlying risk factors

**Table 1** Effects of varying the number of samples from non-suspicious areas in a per lesion analysis

Diagnostic test	Biopsy results		Sensitivity (%)	Specificity (%)	Prevalence (%)
	Positive	Negative			
WLB+AFB					
Test positive	28*	623*			
Test negative					
Original	6*	874*	82.3*	58.4*	2.2*
2 × Original	6 × 2	874 × 2	70.0	73.7	1.7
3 × Original	6 × 3	874 × 3	60.9	80.8	1.4
WLB alone					
Test positive	11*	514*			
Test negative					
Original	8*	843*	57.9*	62.1*	1.4*
2 × Original	8 × 2	843 × 2	40.7	76.6	1.2
3 × Original	8 × 3	843 × 3	31.4	83.1	1.1

WLB, white light bronchoscopy; AFB, autofluorescence bronchoscopy.

\*Figures as reported in the study by Häußinger et al.[1]